Caribou Biosciences, Inc. — Investor Relations & Filings

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative, genome-edited allogeneic cell therapies. The company leverages its proprietary, next-generation CRISPR platform, chRDNA (CRISPR hybrid RNA-DNA) technology, to achieve superior specificity and precision in complex genome editing. Its primary focus is on creating 'off-the-shelf' CAR-T cell therapies for patients with hematologic malignancies and solid tumors. A key component of its strategy is 'armoring' these therapies through multiple genome-editing techniques, such as checkpoint disruption and immune cloaking, to enhance their persistence and anti-tumor activity.